|
|
Affymax, Takeda report Phase 3 data for anemia drug in dialysis patients - NephrOnline |
NephrOnline
These data, along with a demographic analysis from the dialysis studies, were part of three poster presentations at the National Kidney Foundation's Spring Clinical Meetings in Las Vegas. The primary efficacy endpoint for both studies was the ...
Takeda, Affymax announce additional peginesatide Phase 3 study results in
|
|
|
Paricalcitol Use Lower Among Non-Diabetics On Statins - Renal and Urology News |
Renal and Urology News
LAS VEGAS—Statin use by non-diabetic patients with end-stage renal disease may decrease paricalcitol use, according to researchers. In a study of 1894 ESRD patients, Salman R. Mallick, MD, of University Hospitals in Cleveland, and colleagues found
|
|
Partnership expands area dialysis units - Buffalo Business First |
Buffalo Business First
A local group of kidney disease doctors is teaming up with a national dialysis provider to open three new sites in the region. Nephrology Associates of WNY created a new company, Lake Erie Dialysis Providers LLC, which is working with US Renal Care
|
|
Dialysis centers growing to meet demand in capital region - Sacramento Business Journal |
Sacramento Business Journal
The region has at least two dozen outpatient dialysis centers — with Denver-based DaVita Inc. owning more than half. And the numbers are rising. One DaVita center is moving to a larger space to meet demand while another is opening soon.
|
|
Three new dialysis centers coming to suburbs - Buffalo News |
Buffalo News
US Renal Care has started construction on three new dialysis centers in the Buffalo area in a joint venture with a physicians group. This will be the company's first presence in New York State, and comes at a time when most of the 13
|
|
|
|
|
<< Start < Prev 931 932 933 934 935 936 937 938 939 940 Next > End >>
|
|
Page 938 of 2630 |